The object of the present invention relates to the new and surprising use ofsulfated hyaluronic acid (HAS) as regulatoragent of the cytokine activity (pro- and anti- inflammatory) and consequentlythe use of HAS for the preparation of a newmedicine for the prevention and treatment of pathologies associated with theactivation and/or deficiency of cytokines of a proandanti- inflammatory nature. The Applicant has in fact discovered its exclusivecapacity in modulating the activity of these particularproteins, it has studied the action mechanism and demonstrated the substantialdifference between the different sulfatedtypes known in the state of the art, but above all it has demonstrated anunexpectedly high activity of HAS vs different types andstrains of Herpes virus, HN, Cytomegalovirus and the virus of vesicularstomatitis.
